13F Pro

SEC Form 4 reporting owner

Norwalk Leslie V

Norwalk Leslie V has filed 17 Form 4 transactions reported between December 12, 2025 and July 29, 2026, as Director of NEUROCRINE BIOSCIENCES INC, Director of ARVINAS, INC., Director of CVS HEALTH Corp and a reporting owner of GLOBUS MEDICAL INC.

Name as filed: Norwalk Leslie V

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$2.5M
7 lines
Companies
4
with Form 4 filings
Latest transaction
Jul 29, 2026
transaction date

Roles and reported holdings

  • NBIXNEUROCRINE BIOSCIENCES INC
    Dec 15, 2025 – Jul 29, 2026

    Director

    Held directly1,588 sh as of Jul 28, 2026 · Form 4

    24 months: $2.0M sold

  • ARVNARVINAS, INC.
    Jun 24, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • CVSCVS HEALTH Corp
    May 14, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • GMEDGLOBUS MEDICAL INC
    Dec 12, 2025 – Jan 21, 2026

    Reporting owner

    Held directly10,419 sh as of Jan 8, 2026 · Form 4

    24 months: $558K sold

Transaction history

All 17 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Jul 29, 2026NBIXDirectorOption exerciseCode M · direct842$117K@ $139.43Form 4
Jul 28, 2026NBIXDirectorOpen-market saleCode S · direct1,250$228K@ $182.01Form 4
Jun 24, 2026ARVNDirectorGrant or awardCode A · direct22,714—Form 4
Jun 24, 2026ARVNDirectorGrant or awardCode A · direct15,527—Form 4
Jun 4, 2026NBIXDirectorOpen-market saleCode S · direct1,250$210K@ $168.06Form 4
May 27, 2026NBIXDirectorGrant or awardCode A · direct2,624—Form 4
May 27, 2026NBIXDirectorGrant or awardCode A · direct1,284—Form 4
May 21, 2026NBIXDirectorOption exerciseCode M · direct1,659—Form 4
May 14, 2026CVSDirectorGrant or awardCode A · direct1,447$141K@ $97.15Form 4
May 12, 2026NBIXDirectorOpen-market saleCode S · direct3,810$591K@ $155.01Form 4
Jan 21, 2026GMEDGrant or awardCode A · direct15,000—Form 4
Jan 8, 2026GMEDOpen-market saleCode S · direct2,000$202K@ $101.10Form 4
Dec 16, 2025NBIXDirectorOpen-market saleCode S · direct1,190$185K@ $155.09Form 4
Dec 15, 2025NBIXDirectorOpen-market saleCode S · direct5,000$761K@ $152.23Form 4
Dec 15, 2025NBIXDirectorOption exerciseCode M · direct1,724$146K@ $84.95Form 4
Dec 15, 2025NBIXDirectorOption exerciseCode M · direct8,276$764K@ $92.35Form 4
Dec 12, 2025GMEDOpen-market saleCode S · direct4,000$355K@ $88.85Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.